MML Investors Services LLC raised its stake in Astrazeneca PLC (NYSE:AZN) by 9.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 53,422 shares of the company’s stock after buying an additional 4,391 shares during the period. MML Investors Services LLC’s holdings in Astrazeneca PLC were worth $1,821,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of AZN. Bank of America Corp DE increased its holdings in Astrazeneca PLC by 29.5% in the first quarter. Bank of America Corp DE now owns 45,744,976 shares of the company’s stock valued at $1,424,498,000 after buying an additional 10,414,969 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Astrazeneca PLC by 476.9% in the second quarter. Fisher Asset Management LLC now owns 11,081,856 shares of the company’s stock valued at $377,780,000 after buying an additional 9,160,764 shares in the last quarter. Primecap Management Co. CA increased its holdings in Astrazeneca PLC by 32.1% in the first quarter. Primecap Management Co. CA now owns 34,310,950 shares of the company’s stock valued at $1,068,443,000 after buying an additional 8,330,675 shares in the last quarter. BlackRock Inc. increased its holdings in Astrazeneca PLC by 287,844.0% in the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock valued at $215,198,000 after buying an additional 6,908,257 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Astrazeneca PLC by 7.9% in the first quarter. Wellington Management Group LLP now owns 63,250,780 shares of the company’s stock valued at $1,969,630,000 after buying an additional 4,605,694 shares in the last quarter. 14.17% of the stock is owned by institutional investors.

A number of research analysts have issued reports on AZN shares. Barclays PLC reaffirmed an “overweight” rating on shares of Astrazeneca PLC in a report on Monday, July 3rd. BidaskClub cut shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Zacks Investment Research cut shares of Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a report on Monday, July 17th. Finally, Leerink Swann cut shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $36.00 to $31.00 in a report on Thursday, July 27th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $32.70.

Astrazeneca PLC (NYSE AZN) opened at 33.95 on Friday. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60. The firm has a market cap of $85.96 billion, a price-to-earnings ratio of 22.27 and a beta of 0.74. The firm has a 50 day moving average of $30.33 and a 200-day moving average of $31.81. Astrazeneca PLC also was the target of some unusual options trading activity on Wednesday. Stock traders purchased 8,259 put options on the company. This represents an increase of approximately 1,510% compared to the average volume of 513 put options.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the previous year, the business earned $0.83 earnings per share. The firm’s revenue was down 9.9% compared to the same quarter last year. Equities research analysts forecast that Astrazeneca PLC will post $1.90 EPS for the current fiscal year.

The company also recently declared a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were issued a dividend of $0.44 per share. The ex-dividend date of this dividend was Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio is currently 44.92%.

COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC (AZN) Shares Bought by MML Investors Services LLC” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/23/astrazeneca-plc-azn-shares-bought-by-mml-investors-services-llc.html.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.